var data={"title":"Peeling skin syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Peeling skin syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/contributors\" class=\"contributor contributor_credentials\">Eli Sprecher, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/contributors\" class=\"contributor contributor_credentials\">Liat Samuelov, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/contributors\" class=\"contributor contributor_credentials\">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 04, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H109776710\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peeling skin syndrome (PSS) is a heterogeneous group of rare autosomal recessive disorders characterized by superficial painless peeling and blistering of the skin without mucosal fragility [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The two major forms of PSS are acral PSS (APSS) and generalized PSS [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/3-6\" class=\"abstract_t\">3-6</a>]. The latter is subclassified into noninflammatory or type A PSS and inflammatory or type B PSS [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7,8\" class=\"abstract_t\">7,8</a>].</p><p>This topic will review the pathogenesis, clinical features, and management of PSS. Congenital blistering diseases and keratinization disorders are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=epidemiology-pathogenesis-classification-and-clinical-features-of-epidermolysis-bullosa\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, classification, and clinical features of epidermolysis bullosa&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=diagnosis-of-epidermolysis-bullosa\" class=\"medical medical_review\">&quot;Diagnosis of epidermolysis bullosa&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-the-management-of-epidermolysis-bullosa\" class=\"medical medical_review\">&quot;Overview of the management of epidermolysis bullosa&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-and-classification-of-the-inherited-ichthyoses\" class=\"medical medical_review\">&quot;Overview and classification of the inherited ichthyoses&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H109776716\"><span class=\"h1\">ACRAL PEELING SKIN SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acral peeling&nbsp;skin&nbsp;syndrome (APSS, MIM #609796)&nbsp;is a rare autosomal recessive disorder caused by mutations in the <em>TGM5</em> gene, encoding transglutaminase 5 (TGM5) [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/1-3,9\" class=\"abstract_t\">1-3,9</a>]. APSS manifests at birth or in early infancy and is characterized by skin&nbsp;exfoliation limited to the hands and feet.</p><p class=\"headingAnchor\" id=\"H316952002\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The precise incidence and prevalence of APSS are unknown. In European populations, the estimated prevalence of carriers of the p.Gly113Cys mutation in <em>TGM5</em> is approximately 3 percent, predicting a disease frequency of up to 1 in 4500 [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/3,10\" class=\"abstract_t\">3,10</a>]. More than 160 patients with APSS have been reported, with <em>TGM5</em> mutations found in over 90 percent of cases [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/5,9,11\" class=\"abstract_t\">5,9,11</a>]. The vast majority of patients are from European countries, suggesting a founder effect.</p><p class=\"headingAnchor\" id=\"H109776724\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acral peeling skin syndrome (APSS) is caused by biallelic (homozygous or compound heterozygous) mutations in the <em>TGM5</em> gene, encoding transglutaminase 5 (TGM5) [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/3,9\" class=\"abstract_t\">3,9</a>]. Epidermal transglutaminases (TGM) are a family of enzymes involved in the crosslinking of cornified cell envelope proteins through the formation of gamma-glutamyl-lysine isodipeptide bonds between adjacent polypeptides, and hence are crucial for normal epidermal differentiation [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/10,12,13\" class=\"abstract_t\">10,12,13</a>]. Mutations in <em>TGM5</em> completely abolish crosslinking activity, leading to the detachment of the stratum corneum from the underlying stratum granulosum at the site of activity and expression of TGM5 [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/14\" class=\"abstract_t\">14</a>].</p><p><em>TGM5 </em>is located on 15q15.2, spans 33.7 kb of genomic DNA, and contains 13 exons. The TGM5 protein has three domains (beta-sandwich, beta-barrel 1, and beta-barrel 2) and an additional highly conserved, functionally important domain called the central catalytic core [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/5,15\" class=\"abstract_t\">5,15</a>]. Most mutations affect amino acids located in the catalytic core and the beta sandwich domains [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. The most commonly reported mutation, p.Gly113Cys, is located within the beta-sandwich domain and has been found to abolish TGM5 activity [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The high frequency of this mutation in European populations, estimated at approximately 3 percent, most probably reflects a founder effect. There is no obvious phenotype-genotype correlation or variation in severity between homozygous and compound heterozygous patients, but the phenotype can vary in severity both within and between families [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Homozygous mutations in the <em>CSTA</em> gene, encoding cystatin A, a member of a superfamily of protease inhibitors expressed in the cornified cell envelope, were reported in families with APSS without evidence of <em>TGM5 </em>[<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/16,17\" class=\"abstract_t\">16,17</a>]. The same gene has been implicated in the pathogenesis of autosomal recessive exfoliative ichthyosis (MIM #607936), a rare type of congenital ichthyosis characterized by palmoplantar hyperkeratosis with transgression to the dorsal aspects of hands and feet, and acral skin peeling [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/16,18-20\" class=\"abstract_t\">16,18-20</a>].</p><p class=\"headingAnchor\" id=\"H52453532\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>APSS is characterized on histology by compact orthokeratosis and detachment of the stratum corneum from the underlying stratum granulosum [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H109776736\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with APSS present with superficial peeling or blistering of the dorsal surfaces of hands and feet, palms, and soles, often associated with significant erythema [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/21,22\" class=\"abstract_t\">21,22</a>]. Lesions occasionally involve the limbs and may be associated with mild pruritus [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/16,18,23\" class=\"abstract_t\">16,18,23</a>].</p><p>Onset of symptoms is shortly after birth or in early childhood. Healing usually occurs spontaneously, sometimes with residual erythema, burning sensation or pruritus, but without scarring or atrophy. Symptoms are exacerbated by heat, friction, humidity, exposure to water, and trauma [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/21\" class=\"abstract_t\">21</a>].</p><p>There is no obvious phenotype-genotype correlation, but the severity of clinical manifestations can vary both within and between families [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. In most cases, skin peeling persists over time, whereas blistering tends to cease with age [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/23\" class=\"abstract_t\">23</a>]. There are neither systemic manifestations nor abnormal laboratory findings.</p><p class=\"headingAnchor\" id=\"H109776748\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of APSS is suspected in children or adults presenting with acral skin blistering and peeling, in the absence of mucosal involvement. The definitive diagnosis is based upon (<a href=\"image.htm?imageKey=DERM%2F100421\" class=\"graphic graphic_algorithm graphicRef100421 \">algorithm 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histopathologic and ultrastructural analysis of a skin biopsy, demonstrating a cleavage at the junction between stratum corneum and stratum granulosum</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Identification of causative mutations in the <em>TGM5</em> gene by mutation analysis on the DNA isolated from peripheral white blood cells </p><p/><p class=\"headingAnchor\" id=\"H109776754\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of APSS includes several inherited and acquired conditions. APSS is most frequently confused with localized epidermolysis bullosa simplex.</p><p class=\"headingAnchor\" id=\"H316952205\"><span class=\"h3\">Localized epidermolysis bullosa simplex</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Localized epidermolysis bullosa simplex (EBS) is an autosomal dominant disorder most often caused by mutations in the genes <em>KRT5</em> or <em>KRT14</em> and characterized by blisters and erosions on the palms and soles following mechanical trauma (<a href=\"image.htm?imageKey=DERM%2F86390%7EDERM%2F86391\" class=\"graphic graphic_picture graphicRef86390 graphicRef86391 \">picture 1A-B</a>). Ultrastructurally, the blisters are located in the basal layer of the epidermis and not in the upper epidermis as in APSS [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/24,25\" class=\"abstract_t\">24,25</a>]. The diagnosis of APSS should be considered in patients with clinical features of localized EBS who do not have mutation in the <em>KRT5</em> or <em>KRT14</em> genes. Histopathologic and ultrastructural analysis of a skin biopsy and mutation analysis of <em>TGM5</em> can clarify the diagnosis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-classification-and-clinical-features-of-epidermolysis-bullosa#H2900707\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, classification, and clinical features of epidermolysis bullosa&quot;, section on 'Epidermolysis bullosa simplex'</a>.)</p><p class=\"headingAnchor\" id=\"H316952212\"><span class=\"h3\">Exfoliative ichthyosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Exfoliative ichthyosis (EI) is an autosomal recessive disease caused by loss-of-function mutations in <em>CTSA</em>, encoding the protease inhibitor cystatin A. This disorder is characterized by circumscribed, non-erythematous peeling of the skin on the palms and soles, usually associated with generalized dry, scaly skin [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/19\" class=\"abstract_t\">19</a>]. Additional clinical findings include congenital erythroderma and hyperhidrosis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/20\" class=\"abstract_t\">20</a>].</p><p>Ultrastructurally, EI is characterized by impaired desmosome morphology in the lower epidermal layers, reduced thickness of the cornified envelope, disturbed lamellar lipid bilayer, premature lamellar body secretion and delayed processing of secreted lamellar body contents [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/19,20\" class=\"abstract_t\">19,20</a>]. In contrast to PSS, the level of detachment by electron microscopy is in the basal and lower suprabasal layers of the epidermis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H316952219\"><span class=\"h3\">Erythrokeratolysis hiemalis (keratolytic winter erythema)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythrokeratolysis hiemalis is<strong> </strong>an autosomal dominant disorder characterized by cyclic erythema, hyperkeratosis, and peeling of the palms and soles, particularly during the winter. The disease-causing gene was mapped to chromosome 8p22-p23 [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/26\" class=\"abstract_t\">26</a>].</p><p class=\"headingAnchor\" id=\"H109776770\"><span class=\"h3\">Keratolysis exfoliativa</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Keratolysis exfoliativa<strong> </strong>(also known as dyshidrosis lamellosa sicca) is a palmoplantar dermatosis characterized by annular erythema over the volar aspects of the hands and feet with air-filled blisters heralding lamellar peeling. The condition worsens under warm weather and may be associated with hyperhidrosis. Histopathologic findings include cleavage within the stratum corneum without an inflammatory infiltrate [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H109776782\"><span class=\"h3\">Dyshidrotic eczema</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dyshidrotic eczema is characterized by eruptive pruritic fluid-filled vesicles, mainly on the lateral aspects of the fingers, the palms, and occasionally on the soles (<a href=\"image.htm?imageKey=PC%2F55722%7EPC%2F75738\" class=\"graphic graphic_picture graphicRef55722 graphicRef75738 \">picture 2A-B</a>). The condition is more common in patients with a history of atopic dermatitis, allergic and irritant contact dermatitis, and in patients sensitized to nickel, cobalt, or chromate [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=acute-palmoplantar-eczema-dyshidrotic-eczema\" class=\"medical medical_review\">&quot;Acute palmoplantar eczema (dyshidrotic eczema)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H109776788\"><span class=\"h3\">Fungal infection and dermatophytid reaction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vesiculobullous tinea pedis is characterized by pustules or vesicles on the instep and adjacent plantar surfaces of the feet (<a href=\"image.htm?imageKey=DERM%2F82787\" class=\"graphic graphic_picture graphicRef82787 \">picture 3</a>). This form of tinea pedis may be associated with dermatophytid reaction. Potassium hydroxide (KOH) preparations and fungal culture of the vesicles aspirate should be performed to confirm the diagnosis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections#H15\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;, section on 'Tinea pedis'</a>.)</p><p>A dermatophytid reaction presents with vesicular hand eczema (<a href=\"image.htm?imageKey=DERM%2F52664\" class=\"graphic graphic_picture graphicRef52664 \">picture 4</a>) that in most cases follows interdigital or vesiculobullous tinea infection of the feet or tinea capitis. It may be clinically indistinguishable from dyshidrotic eczema or may present as a squamous form that resembles dyshidrosis lamellosa sicca [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/28,30,31\" class=\"abstract_t\">28,30,31</a>]. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections#H4733135\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;, section on 'Dermatophytid (id) reactions'</a>.)</p><p class=\"headingAnchor\" id=\"H109776800\"><span class=\"h3\">Allergic contact dermatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Allergic contact dermatitis may present as vesicular hand eczema or chronic fissured hand eczema. Metals (eg, nickel sulphate, cobalt chloride), fragrances, and preservatives (eg, methylchloroisothiazolinone, methylisothiazolinone, methyldibromo glutaronitrile) are among the most frequent sensitizers. Patch testing is indicated to establish the diagnosis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/32-34\" class=\"abstract_t\">32-34</a>]. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of allergic contact dermatitis&quot;</a> and <a href=\"topic.htm?path=common-allergens-in-allergic-contact-dermatitis\" class=\"medical medical_review\">&quot;Common allergens in allergic contact dermatitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H109776806\"><span class=\"h3\">Autoimmune bullous disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bullous pemphigoid can manifest as a vesicular palmar <span class=\"nowrap\">and/or</span> plantar eruption (<a href=\"image.htm?imageKey=DERM%2F50357\" class=\"graphic graphic_picture graphicRef50357 \">picture 5</a>). The lesions may be hemorrhagic. Similar findings have been described in linear IgA diseases (<a href=\"image.htm?imageKey=DERM%2F100995\" class=\"graphic graphic_picture graphicRef100995 \">picture 6</a>) and in herpes gestationis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/35-38\" class=\"abstract_t\">35-38</a>].</p><p class=\"headingAnchor\" id=\"H109776812\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no specific therapy for APSS. Patients should be educated about avoidance of exacerbating factors such as heat, friction, humidity, mechanical trauma, and excessive perspiration. Daily topical application of emollients to affected areas may be beneficial.</p><p class=\"headingAnchor\" id=\"H316952558\"><span class=\"h2\">Genetic testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients and their family members should be referred for genetic counseling. In patients of European ancestry suspected to have EBS but lacking mutations in the keratin genes, screening for the recurrent <em>TGM5</em> mutation p.Gly113Cys is indicated.</p><p class=\"headingAnchor\" id=\"H109776818\"><span class=\"h1\">GENERALIZED NONINFLAMMATORY PEELING SKIN SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Generalized noninflammatory peeling skin syndrome or type A PSS (MIM #270300) is a rare autosomal recessive disorder caused by homozygous mutations in the <em>CHST8</em> gene, encoding a Golgi transmembrane carbohydrate sulfotransferase [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Type A PSS is characterized by generalized painless peeling of the skin starting at birth or in early infancy.</p><p class=\"headingAnchor\" id=\"H109776826\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Using a combination of autozygosity mapping and whole-exome sequencing in a large consanguineous Pakistani family, type A PSS has been found to be caused by a homozygous mutation, c.229C&gt;T, within exon 4 of the <em>CHST8</em> gene [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7\" class=\"abstract_t\">7</a>]. The mutation results in arginine to tryptophan substitution in position 77 of the CHST8 protein sequence [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7\" class=\"abstract_t\">7</a>].</p><p><em>CHST8</em> encodes a carbohydrate sulfotransferase, N-acetylgalactosamine-4-O-sulfotransferase 1 (GalNAc4-ST1). This enzyme is a type II transmembrane protein that functions almost exclusively in the Golgi apparatus and transfers sulfate groups to the C4 hydroxyl group of terminal beta-1,4-linked N-acetylgalactosamine [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/39\" class=\"abstract_t\">39</a>]. GalNAc4-ST1 is specific for oligosaccharides on glycoproteins terminating with beta-1,4-linked GalNAc-4-SO4, such as carbonic anhydrase VI, tenascin R, chondroitin, keratin sulfate, heparan sulfate, and proopiomelanocortin (POMC), many of which are expressed by human keratinocytes [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/39\" class=\"abstract_t\">39</a>].</p><p>GalNAc4-ST1 is highly expressed in the pituitary gland, cerebellum, and brain, and is required for the biosynthesis of the glycoprotein hormones LH and thyrotropin [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/39\" class=\"abstract_t\">39</a>]. GalNAc4-ST1 is also expressed throughout the human epidermis, with highest expression levels in suprabasal layers, suggesting that it may play a role in epidermal differentiation [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7\" class=\"abstract_t\">7</a>].</p><p>The missense mutation c.229C&gt;T involves the Golgi luminal domain of GalNAc4-ST1 and is predicted to perturb amino acid hydrophilicity due to the substitution of the basic amino acid arginine to the non-polar amino acid tryptophan, resulting in a mutant GalNAc4-ST1 protein, which is subjected to increased degradation due to reduced glycosylation [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H316952681\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type A PSS is characterized by slight hyperkeratosis, thinning of the granular layer, and separation of the stratum corneum from the underlying stratum granulosum or intracorneal split [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/40\" class=\"abstract_t\">40</a>]. Electron microscopy shows intracellular cytoplasmic splitting in the lower stratum corneum and abnormal cribriform keratohyalin granules, which are indicative of disturbed keratinization. In some patients, reduced desmosomal plaques or intracellular electron-dense globular deposits within the stratum corneum have also been observed [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/41-43\" class=\"abstract_t\">41-43</a>].</p><p class=\"headingAnchor\" id=\"H109776832\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type A PSS presents at birth or early childhood with generalized white scaling, most prominent over the upper and lower extremities, with painless and easy removal of the skin [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/44\" class=\"abstract_t\">44</a>]. Thickened skin over the palms and soles may be an associated finding. Peeling is generally less prominent on acral than non-acral areas [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/45\" class=\"abstract_t\">45</a>]. Exacerbations may occur following contact with water, dust, and sand. In addition, sliding forces may induce peeling [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Erythema, pruritus, and atopic manifestations, as well as hair, nail, and mucous abnormalities, and systemic involvement are usually absent [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7\" class=\"abstract_t\">7</a>]. Routine laboratory tests, including IgE serum levels, are normal. There is a single case report of type A PSS associated with aminoaciduria, with increased urine excretion of cystine and histidine [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/46\" class=\"abstract_t\">46</a>].</p><p class=\"headingAnchor\" id=\"H109776844\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of type A PSS is often delayed due to late presentation in less severe and asymptomatic cases. As for APSS, the diagnosis of type A PSS is suspected in a patient presenting with painless skin peeling since birth or early childhood. A skin biopsy for histopathologic and ultrastructural analysis is necessary for the diagnosis (see <a href=\"#H316952681\" class=\"local\">'Pathology'</a> above). Molecular analysis for mutations in <em>CHST8 </em>is indicated in patients and family members for definitive diagnosis (<a href=\"image.htm?imageKey=DERM%2F100421\" class=\"graphic graphic_algorithm graphicRef100421 \">algorithm 1</a>).</p><p class=\"headingAnchor\" id=\"H109776850\"><span class=\"h2\">Differential diagnosis</span></p><p class=\"headingAnchor\" id=\"H109776857\"><span class=\"h3\">Staphylococcal scalded skin syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Staphylococcal scalded skin syndrome (SSSS) is caused by certain strains of <em>Staphylococcus aureus</em>, which release exfoliative toxin (serine protease) capable of cleaving desmoglein 1 in the superficial epidermis, resulting in impaired cell adhesion, blistering, and superficial denuding of the skin (<a href=\"image.htm?imageKey=DERM%2F72261\" class=\"graphic graphic_picture graphicRef72261 \">picture 7</a>) [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/47\" class=\"abstract_t\">47</a>]. The disorder is most frequently seen in infants and young children and is associated with irritability, malaise, fever, and skin pain. The diagnosis is based upon the clinical presentation, positivity of the Nikolsky sign, and histopathologic examination of a skin biopsy. <em>Staphylococcus aureus </em>can be isolated from the primary site of infection, especially the nasopharynx or conjunctiva. (See <a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant#H8\" class=\"medical medical_review\">&quot;Vesiculopustular and bullous lesions in the newborn and infant&quot;, section on 'Staphylococcal scalded skin syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H109776863\"><span class=\"h3\">Epidermolysis bullosa simplex superficialis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epidermolysis bullosa simplex superficialis (EBSS) is a subtype of EBS associated with superficial blisters, peeling, and histopathologic evidence of subcorneal cleavage. Whether this disorder represents a separate entity is still a matter of debate. The original EBSS case was found to be due to a mutation in <em>COL7A1</em>, a gene associated with dystrophic epidermolysis bullosa. Patients with APSS sometimes display peeling that extends beyond acral sites [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/10,23,24\" class=\"abstract_t\">10,23,24</a>]. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-classification-and-clinical-features-of-epidermolysis-bullosa#H2900707\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, classification, and clinical features of epidermolysis bullosa&quot;, section on 'Epidermolysis bullosa simplex'</a>.)</p><p class=\"headingAnchor\" id=\"H109776869\"><span class=\"h3\">Superficial epidermolytic ichthyosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Superficial epidermolytic ichthyosis is a rare autosomal dominant genodermatosis caused by heterozygous mutations in the gene <em>KRT2</em> encoding keratin 2. The disease is characterized by mild blistering in early infancy that usually subsides by early childhood when hyperkeratosis develops. An additional characteristic feature is superficial peeling described as &quot;Mauserung (moulting) phenomenon,&quot; secondary to superficial blistering and shedding of the stratum corneum [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/48\" class=\"abstract_t\">48</a>]. (See <a href=\"topic.htm?path=overview-and-classification-of-the-inherited-ichthyoses#H16647254\" class=\"medical medical_review\">&quot;Overview and classification of the inherited ichthyoses&quot;, section on 'Epidermolytic ichthyosis'</a>.)</p><p class=\"headingAnchor\" id=\"H109776875\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no specific therapy for type A PSS. Patients should be educated about avoiding exacerbating factors such as heat, friction, humidity, mechanical trauma, and excessive perspiration. Daily topical application of emollients to affected areas may be beneficial.</p><p>Systemic retinoids, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, topical and systemic corticosteroids, tar, and ultraviolet B (UVB) phototherapy have been used without success in a few patients [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/1,42,44,49-51\" class=\"abstract_t\">1,42,44,49-51</a>]. Some improvement with topical <a href=\"topic.htm?path=calcipotriol-calcipotriene-drug-information\" class=\"drug drug_general\">calcipotriol</a> has been documented in a single patient [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"headingAnchor\" id=\"H109776881\"><span class=\"h1\">GENERALIZED INFLAMMATORY PEELING SKIN SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Generalized inflammatory peeling skin syndrome or type B PSS (MIM #270300) is a rare autosomal recessive genodermatosis that results from loss-of-function mutations in the <em>CDSN</em> gene, encoding corneodesmosin (CDSN) [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/8\" class=\"abstract_t\">8</a>]. Type B PSS presents at birth or in early childhood with widespread peeling of the skin associated with erythroderma, severe pruritus, and atopic manifestations.</p><p class=\"headingAnchor\" id=\"H109776889\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type B PSS is caused by loss-of-function mutations in <em>CDSN</em>, encoding corneodesmosin, with complete loss of protein expression in the epidermis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/8,53-55\" class=\"abstract_t\">8,53-55</a>]. Genomic deletion at the PSORS1 locus removing the entire <em>CDSN </em>gene and a large homozygous deletion of six genes including <em>CDSN </em>have also been<em> </em>reported as the cause of type B PSS [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/56,57\" class=\"abstract_t\">56,57</a>]. This genomic deletion resulting from a founder mutation has been identified in several Japanese patients with PSS [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/58\" class=\"abstract_t\">58</a>].</p><p>Corneodesmosin is an extracellular 52 to 56 kDa glycoprotein that contributes to the formation of corneodesmosomes, critical intercellular junctions in the upper epidermal layers. This protein plays a role in reinforcing cell-cell adhesion in the upper epidermis, and its degradation by epidermal proteases is essential for normal desquamation [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/59,60\" class=\"abstract_t\">59,60</a>]. The absence of corneodesmosin in patients with type B PSS results in impaired cell-cell coherence in the upper epidermis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/61\" class=\"abstract_t\">61</a>]. The defective skin barrier function leads to increased permeability to allergens and microbes, predisposing to atopic manifestations and skin infections [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"headingAnchor\" id=\"H316952963\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On histology, type B PSS shows subcorneal separation with mild inflammatory infiltrate in the upper dermis. Electron microscopy shows evidence of split formation between the keratinocytes of the stratum granulosum and corneocytes of the stratum corneum and loss of corneodesmosomes [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/8\" class=\"abstract_t\">8</a>]. Total absence of corneodesmosin expression in the epidermis demonstrated by immunohistochemistry can confirm the diagnosis.</p><p class=\"headingAnchor\" id=\"H109776895\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type B PSS presents at birth or during early infancy with spontaneous and widespread peeling of the skin associated with erythroderma. Additional major features are severe pruritus, food allergies, asthma, repeated episodes of angioedema, and urticaria. Patients may exhibit failure to thrive and recurrent skin infections, especially with <em>Staphylococcus aureus </em>[<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/8,53,55\" class=\"abstract_t\">8,53,55</a>]. There are no hair abnormalities.</p><p>Characteristic laboratory findings are elevated immunoglobulin E (IgE) levels and eosinophilia. Elevated serum copper and ceruloplasmin, high serum iron and iron-binding capacity, altered epidermal retinoid metabolism, abnormal plasma tryptophan, and reduced plasma cysteine and hydroxyproline levels have also been rarely reported [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/1,22,42,62\" class=\"abstract_t\">1,22,42,62</a>].</p><p>There is a single-case report of type B peeling skin syndrome with recurrent skin infections associated with IgA nephropathy [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/63\" class=\"abstract_t\">63</a>].</p><p class=\"headingAnchor\" id=\"H109776907\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of type B PSS is based upon the combination of clinical and laboratory findings (<a href=\"image.htm?imageKey=DERM%2F100421\" class=\"graphic graphic_algorithm graphicRef100421 \">algorithm 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Widespread skin peeling associated with erythroderma, severe pruritus, and atopic manifestations, including food allergies and asthma</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated levels of serum IgE and eosinophilia</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histopathologic findings of subcorneal separation with mild inflammatory infiltrate in the upper dermis and absent corneodesmosin stain on immunohistochemistry</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evidence of loss of corneodesmosomes on electron microscopy</p><p/><p class=\"headingAnchor\" id=\"H109776913\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of type B PSS includes several acquired and inherited disorders. Due to considerable phenotypic overlap, the differentiation of type B PSS from Netherton syndrome (NS) and severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome requires mutational analysis [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/41,61\" class=\"abstract_t\">41,61</a>].</p><p class=\"headingAnchor\" id=\"H109776921\"><span class=\"h3\">Atopic dermatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic skin condition resulting from disruption of the epithelial barrier and associated immune dysregulation in the skin of genetically predisposed individuals. AD generally develops in early childhood (10 to 20 percent of children in developed countries are affected), has a characteristic age-dependent distribution of eczematous skin eruption, and is commonly associated with elevated IgE, peripheral eosinophilia, and atopy [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/64\" class=\"abstract_t\">64</a>]. Active lesions of AD exhibit aberrant expression of desmosomal proteins such as DSG1 and CDSN [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/65\" class=\"abstract_t\">65</a>]. Those findings may explain the phenotypic similarities between type B PSS and AD [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/66\" class=\"abstract_t\">66</a>]. (See <a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H316953004\"><span class=\"h3\">Netherton syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Netherton syndrome (NS, MIM #256500) is an autosomal recessive genodermatosis caused by loss-of-function mutations in the serine protease inhibitor of Kazal type 5 <em>(SPINK5</em>) gene, encoding the serine protease inhibitor lympho-epithelial Kazal type related inhibitor type 5 (LEKTI) [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/67-69\" class=\"abstract_t\">67-69</a>]. NS is characterized by congenital erythroderma, occasionally complicated with hypernatremic dehydration and sepsis, which usually evolves into a widespread eruption consisting of serpiginous plaques with typical double-edged scales, known as ichthyosis linearis circumflexa (<a href=\"image.htm?imageKey=DERM%2F87482\" class=\"graphic graphic_picture graphicRef87482 \">picture 8</a>) [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/70-74\" class=\"abstract_t\">70-74</a>]. Eosinophilia and elevated IgE levels [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/75\" class=\"abstract_t\">75</a>] are common laboratory findings. Additional clinical findings include eczematous atopic dermatitis-like lesions, characteristic hair abnormalities (trichorrhexis invaginata) (<a href=\"image.htm?imageKey=DERM%2F87481\" class=\"graphic graphic_picture graphicRef87481 \">picture 9</a>), failure to thrive, atopic manifestations (eg, asthma, allergic rhinitis, food allergies), urticaria, angioedema, and often severe reactions [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/76-80\" class=\"abstract_t\">76-80</a>]. (See <a href=\"topic.htm?path=overview-and-classification-of-the-inherited-ichthyoses#H5808386\" class=\"medical medical_review\">&quot;Overview and classification of the inherited ichthyoses&quot;, section on 'Netherton syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H316953017\"><span class=\"h3\">SAM syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome (MIM #615508) is a new genodermatosis first described in 2013, caused by homozygous mutations in <em>DSG1</em>, encoding desmoglein 1, a cadherin-like transmembrane glycoprotein that is an essential component of the desmosomes in the upper epidermal layers [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/81-84\" class=\"abstract_t\">81-84</a>]. There is a single case report of SAM syndrome caused by a point mutation in the <em>DSP</em> gene encoding desmoplakin [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/85\" class=\"abstract_t\">85</a>]. Desmoplakin is an obligate component of functional desmosomes that anchors intermediate filaments to desmosomal plaques.</p><p>SAM syndrome is characterized by congenital erythroderma, striate palmoplantar keratoderma (yellowish papules and plaques at the periphery of the palms, along the fingers, and over weight-bearing areas of the feet), skin erosions, scaling, and hypotrichosis. Additional features are severe food allergies, recurrent skin and respiratory infections, eosinophilic esophagitis, esophageal reflux, minor cardiac defects, failure to thrive, and growth retardation. Elevated IgE level is a common laboratory finding [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/61,66,81-84,86,87\" class=\"abstract_t\">61,66,81-84,86,87</a>]. </p><p class=\"headingAnchor\" id=\"H316953034\"><span class=\"h3\">Hyper-IgE syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hyper-IgE syndrome (HIES) is an autosomal dominant disorder characterized by eosinophilia, elevated IgE levels, eczema, atopy, recurrent skin and pulmonary infections (eg, staphylococcal cold abscess, chronic mucocutaneous candidiasis), and different somatic manifestations (eg, craniofacial, vascular abnormalities) (<a href=\"image.htm?imageKey=ALLRG%2F61049\" class=\"graphic graphic_picture graphicRef61049 \">picture 10</a>). HIES is caused by dominant mutations in the gene <em>STAT3</em>, encoding the signal transducer and activator of transcription 3, a component of the JAK-STAT pathway of signal transduction [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/88\" class=\"abstract_t\">88</a>]. (See <a href=\"topic.htm?path=autosomal-dominant-hyperimmunoglobulin-e-syndrome\" class=\"medical medical_review\">&quot;Autosomal dominant hyperimmunoglobulin E syndrome&quot;</a>.)</p><p>Some patients with combined immunodeficiencies due to mutations in the genes <em>TYK2</em> or <em>DOCK8</em> were previously thought to have milder autosomal recessive HIES because of similarities in clinical presentation [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/88\" class=\"abstract_t\">88</a>]. (See <a href=\"topic.htm?path=combined-immunodeficiencies#H26880425\" class=\"medical medical_review\">&quot;Combined immunodeficiencies&quot;, section on 'Serine threonine kinase 4 deficiency'</a> and <a href=\"topic.htm?path=combined-immunodeficiencies#H31\" class=\"medical medical_review\">&quot;Combined immunodeficiencies&quot;, section on 'Dedicator of cytokinesis 8 deficiency'</a>.)</p><p class=\"headingAnchor\" id=\"H109776934\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no specific therapy for type B PSS. Patients should be educated about avoidance of exacerbating factors such as heat, friction, humidity, mechanical trauma, and excessive perspiration. Daily topical application of emollients to affected areas may be beneficial.</p><p>A role for antihistamines and kallikrein inhibitors in the treatment of type B PSS has been hypothesized, based upon the observation in vitro that histamine attenuates the expression of desmosomal proteins including CDSN in human keratinocytes and kallikreins are upregulated in type B PSS [<a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/89-95\" class=\"abstract_t\">89-95</a>]. However, due to the rarity of type B PSS, clinical experience with these agents is lacking.</p><p class=\"headingAnchor\" id=\"H316953238\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peeling skin syndrome (PSS) is a heterogeneous group of rare autosomal recessive disorders characterized by superficial painless peeling and blistering of the skin without mucosal fragility. The two major forms of PSS are acral PSS (APSS) and generalized PSS. The latter is subclassified into noninflammatory or type A PSS and inflammatory or type B PSS. (See <a href=\"#H109776710\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>APSS&nbsp;is caused by mutations in the <em>TGM5</em> gene, encoding transglutaminase 5 (TGM5), involved in the crosslinking of cornified cell envelope proteins. APSS manifests at birth or in early infancy and is characterized by skin&nbsp;exfoliation limited to the hands and feet. (See <a href=\"#H109776716\" class=\"local\">'Acral peeling skin syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Generalized noninflammatory peeling skin syndrome, or type A PSS (MIM #270300), is caused by a homozygous mutation in the <em>CHST8</em> gene, encoding a Golgi apparatus carbohydrate sulfotransferase. Type A PSS presents at birth or early childhood with generalized white scaling, most prominent over the upper and lower extremities, with painless and easy removal of the skin. (See <a href=\"#H109776818\" class=\"local\">'Generalized noninflammatory peeling skin syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Generalized inflammatory peeling skin syndrome, or type B PSS (MIM #270300), is caused by loss-of-function mutations in the <em>CDSN</em> gene, encoding corneodesmosin (CDSN). Type B PSS presents at birth or in early childhood with widespread peeling of the skin associated with erythroderma, severe pruritus, and atopic manifestations. (See <a href=\"#H109776881\" class=\"local\">'Generalized inflammatory peeling skin syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of PSS is based upon the combination of clinical features, routine laboratory tests, histopathologic and ultrastructural analysis of a skin biopsy, and mutation analysis (<a href=\"image.htm?imageKey=DERM%2F100421\" class=\"graphic graphic_algorithm graphicRef100421 \">algorithm 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no specific therapy for PSS. Avoidance of exacerbating factors such as heat, friction, humidity, mechanical trauma, and excessive perspiration, as well as daily topical application of emollients to affected areas are the mainstay of treatment.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/1\" class=\"nounderline abstract_t\">Levy SB, Goldsmith LA. The peeling skin syndrome. J Am Acad Dermatol 1982; 7:606.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/2\" class=\"nounderline abstract_t\">Hacham-Zadeh S, Holubar K. Skin peeling syndrome in a Kurdish family. Arch Dermatol 1985; 121:545.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/3\" class=\"nounderline abstract_t\">Cassidy AJ, van Steensel MA, Steijlen PM, et al. A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome. Am J Hum Genet 2005; 77:909.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/4\" class=\"nounderline abstract_t\">Kharfi M, El Fekih N, Ammar D, et al. A missense mutation in TGM5 causes acral peeling skin syndrome in a Tunisian family. J Invest Dermatol 2009; 129:2512.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/5\" class=\"nounderline abstract_t\">Szczecinska W, Nesteruk D, Wertheim-Tysarowska K, et al. Under-recognition of acral peeling skin syndrome: 59 new cases with 15 novel mutations. Br J Dermatol 2014; 171:1206.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/6\" class=\"nounderline abstract_t\">Shwayder T, Conn S, Lowe L. Acral peeling skin syndrome. Arch Dermatol 1997; 133:535.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/7\" class=\"nounderline abstract_t\">Cabral RM, Kurban M, Wajid M, et al. Whole-exome sequencing in a single proband reveals a mutation in the CHST8 gene in autosomal recessive peeling skin syndrome. Genomics 2012; 99:202.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/8\" class=\"nounderline abstract_t\">Oji V, Eckl KM, Aufenvenne K, et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet 2010; 87:274.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/9\" class=\"nounderline abstract_t\">van der Velden JJ, van Geel M, Nellen RG, et al. Novel TGM5 mutations in acral peeling skin syndrome. Exp Dermatol 2015; 24:285.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/10\" class=\"nounderline abstract_t\">Pigors M, Kiritsi D, Cobzaru C, et al. TGM5 mutations impact epidermal differentiation in acral peeling skin syndrome. J Invest Dermatol 2012; 132:2422.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/11\" class=\"nounderline abstract_t\">Ca&ntilde;ueto J, Bueno E, Rodr&iacute;guez-Diaz E, et al. Acral peeling skin syndrome resulting from mutations in TGM5. J Eur Acad Dermatol Venereol 2016; 30:477.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/12\" class=\"nounderline abstract_t\">Kalinin AE, Kajava AV, Steinert PM. Epithelial barrier function: assembly and structural features of the cornified cell envelope. Bioessays 2002; 24:789.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/13\" class=\"nounderline abstract_t\">Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005; 6:328.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/14\" class=\"nounderline abstract_t\">Garc&iacute;a EG, Carre&ntilde;o RG, Mart&iacute;nez Gonz&aacute;lez MA, Reyes JJ. Acral peeling skin syndrome: report of two cases. Ultrastruct Pathol 2005; 29:65.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/15\" class=\"nounderline abstract_t\">Grenard P, Bates MK, Aeschlimann D. Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 2001; 276:33066.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/16\" class=\"nounderline abstract_t\">Krunic AL, Stone KL, Simpson MA, McGrath JA. Acral peeling skin syndrome resulting from a homozygous nonsense mutation in the CSTA gene encoding cystatin A. Pediatr Dermatol 2013; 30:e87.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/17\" class=\"nounderline abstract_t\">Muttardi K, Nitoiu D, Kelsell DP, et al. Acral peeling skin syndrome associated with a novel CSTA gene mutation. Clin Exp Dermatol 2016; 41:394.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/18\" class=\"nounderline abstract_t\">Pavlovic S, Krunic AL, Bulj TK, et al. Acral peeling skin syndrome: a clinically and genetically heterogeneous disorder. Pediatr Dermatol 2012; 29:258.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/19\" class=\"nounderline abstract_t\">Blaydon DC, Nitoiu D, Eckl KM, et al. Mutations in CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion. Am J Hum Genet 2011; 89:564.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/20\" class=\"nounderline abstract_t\">Moosbrugger-Martinz V, Jalili A, Schossig AS, et al. Epidermal barrier abnormalities in exfoliative ichthyosis with a novel homozygous loss-of-function mutation in CSTA. Br J Dermatol 2015; 172:1628.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/21\" class=\"nounderline abstract_t\">Kavaklieva S, Yordanova I, Bruckner-Tuderman L, Has C. Acral peeling skin syndrome resembling epidermolysis bullosa simplex in a 10-month-old boy. Case Rep Dermatol 2013; 5:210.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/22\" class=\"nounderline abstract_t\">Hashimoto K, Hamzavi I, Tanaka K, Shwayder T. Acral peeling skin syndrome. J Am Acad Dermatol 2000; 43:1112.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/23\" class=\"nounderline abstract_t\">Kiritsi D, Cosgarea I, Franzke CW, et al. Acral peeling skin syndrome with TGM5 gene mutations may resemble epidermolysis bullosa simplex in young individuals. J Invest Dermatol 2010; 130:1741.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/24\" class=\"nounderline abstract_t\">Has C, Bruckner-Tuderman L. The genetics of skin fragility. Annu Rev Genomics Hum Genet 2014; 15:245.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/25\" class=\"nounderline abstract_t\">Lane EB, McLean WH. Keratins and skin disorders. J Pathol 2004; 204:355.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/26\" class=\"nounderline abstract_t\">Starfield M, Hennies HC, Jung M, et al. Localization of the gene causing keratolytic winter erythema to chromosome 8p22-p23, and evidence for a founder effect in South African Afrikaans-speakers. Am J Hum Genet 1997; 61:370.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/27\" class=\"nounderline abstract_t\">Chang YY, van der Velden J, van der Wier G, et al. Keratolysis exfoliativa (dyshidrosis lamellosa sicca): a distinct peeling entity. Br J Dermatol 2012; 167:1076.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/28\" class=\"nounderline abstract_t\">Veien NK. Acute and recurrent vesicular hand dermatitis. Dermatol Clin 2009; 27:337.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/29\" class=\"nounderline abstract_t\">Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy 2004; 2:5.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/30\" class=\"nounderline abstract_t\">Liu ZH, Shen H, Xu AE. Severe kerion with dermatophytid reaction presenting with diffuse erythema and pustules. Mycoses 2011; 54:e650.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/31\" class=\"nounderline abstract_t\">Romano C, Rubegni P, Ghilardi A, Fimiani M. A case of bullous tinea pedis with dermatophytid reaction caused by Trichophyton violaceum. Mycoses 2006; 49:249.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/32\" class=\"nounderline abstract_t\">Boonstra MB, Christoffers WA, Coenraads PJ, Schuttelaar ML. Patch test results of hand eczema patients: relation to clinical types. J Eur Acad Dermatol Venereol 2015; 29:940.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/33\" class=\"nounderline abstract_t\">Isaksson M, Olhardt S, R&aring;dehed J, Svensson &Aring;. Children with Atopic Dermatitis Should Always be Patch-tested if They Have Hand or Foot Dermatitis. Acta Derm Venereol 2015; 95:583.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/34\" class=\"nounderline abstract_t\">Lachapelle JM. Allergic contact dermatitis: clinical aspects. Rev Environ Health 2014; 29:185.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/35\" class=\"nounderline abstract_t\">Barth JH, Fairris GM, Wojnarowska F, White JE. Haemorrhagic pompholyx is a sign of bullous pemphigoid and an indication for low-dose prednisolone therapy. Clin Exp Dermatol 1986; 11:409.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/36\" class=\"nounderline abstract_t\">Barth JH, Venning VA, Wojnarowska F. Palmo-plantar involvement in auto-immune blistering disorders--pemphigoid, linear IgA disease and herpes gestationis. Clin Exp Dermatol 1988; 13:85.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/37\" class=\"nounderline abstract_t\">Duhra P, Charles-Holmes R. Linear IgA disease with haemorrhagic pompholyx and dapsone-induced neutropenia. Br J Dermatol 1991; 125:172.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/38\" class=\"nounderline abstract_t\">Sugimura C, Katsuura J, Moriue T, et al. Dyshidrosiform pemphigoid: report of a case. J Dermatol 2003; 30:525.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/39\" class=\"nounderline abstract_t\">Baenziger JU. Glycoprotein hormone GalNAc-4-sulphotransferase. Biochem Soc Trans 2003; 31:326.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/40\" class=\"nounderline abstract_t\">Garg K, Singh D, Mishra D. Peeling skin syndrome: Current status. Dermatol Online J 2010; 16:10.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/41\" class=\"nounderline abstract_t\">Ishida-Yamamoto A, Igawa S, Kishibe M. Order and disorder in corneocyte adhesion. J Dermatol 2011; 38:645.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/42\" class=\"nounderline abstract_t\">Mevorah B, Frenk E, Saurat JH, Siegenthaler G. Peeling skin syndrome: a clinical, ultrastructural and biochemical study. Br J Dermatol 1987; 116:117.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/43\" class=\"nounderline abstract_t\">Silverman AK, Ellis CN, Beals TF, Woo TY. Continual skin peeling syndrome. An electron microscopic study. Arch Dermatol 1986; 122:71.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/44\" class=\"nounderline abstract_t\">Sarma N, Boler AK, Bhanja DC. Peeling skin syndrome in eight cases of four different families from India and Bangladesh. Indian J Dermatol Venereol Leprol 2012; 78:625.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/45\" class=\"nounderline abstract_t\">Aras N, Sutman K, Tastan HB, et al. Peeling skin syndrome. J Am Acad Dermatol 1994; 30:135.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/46\" class=\"nounderline abstract_t\">Inamadar AC, Palit A. Peeling skin syndrome with aminoaciduria. Pediatr Dermatol 2005; 22:314.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/47\" class=\"nounderline abstract_t\">Handler MZ, Schwartz RA. Staphylococcal scalded skin syndrome: diagnosis and management in children and adults. J Eur Acad Dermatol Venereol 2014; 28:1418.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/48\" class=\"nounderline abstract_t\">Cervantes T, Pham C, Browning JC. Superficial epidermolytic ichthyosis: a report of two families. Pediatr Dermatol 2013; 30:469.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/49\" class=\"nounderline abstract_t\">Tolat SN, Gharpuray MB. Skin peeling syndrome. Cutis 1994; 53:255.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/50\" class=\"nounderline abstract_t\">K&ouml;se O, Safali M, Ko&ccedil; E, et al. Peeling skin diseases: 21 cases from Turkey and a review of the literature. J Eur Acad Dermatol Venereol 2012; 26:844.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/51\" class=\"nounderline abstract_t\">Kharfi M, Khaled A, Ammar D, et al. Generalized peeling skin syndrome: Case report and review of the literature. Dermatol Online J 2010; 16:1.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/52\" class=\"nounderline abstract_t\">Mizuno Y, Suga Y, Hasegawa T, et al. A case of peeling skin syndrome successfully treated with topical calcipotriol. J Dermatol 2006; 33:430.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/53\" class=\"nounderline abstract_t\">Israeli S, Zamir H, Sarig O, et al. Inflammatory peeling skin syndrome caused by a mutation in CDSN encoding corneodesmosin. J Invest Dermatol 2011; 131:779.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/54\" class=\"nounderline abstract_t\">Mallet A, Kypriotou M, George K, et al. Identification of the first nonsense CDSN mutation with expression of a truncated protein causing peeling skin syndrome type B. Br J Dermatol 2013; 169:1322.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/55\" class=\"nounderline abstract_t\">Telem DF, Israeli S, Sarig O, Sprecher E. Inflammatory peeling skin syndrome caused a novel mutation in CDSN. Arch Dermatol Res 2012; 304:251.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/56\" class=\"nounderline abstract_t\">Ishida-Yamamoto A, Furio L, Igawa S, et al. Inflammatory peeling skin syndrome caused by homozygous genomic deletion in the PSORS1 region encompassing the CDSN gene. Exp Dermatol 2014; 23:60.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/57\" class=\"nounderline abstract_t\">Teye K, Hamada T, Krol RP, et al. Homozygous deletion of six genes including corneodesmosin on chromosome 6p21.3 is associated with generalized peeling skin disease. J Dermatol Sci 2014; 75:36.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/58\" class=\"nounderline abstract_t\">Teye K, Suga Y, Numata S, et al. A founder deletion of corneodesmosin gene is prevalent in Japanese patients with peeling skin disease: Identification of 2 new cases. J Dermatol Sci 2016; 82:134.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/59\" class=\"nounderline abstract_t\">Caubet C, Jonca N, Lopez F, et al. Homo-oligomerization of human corneodesmosin is mediated by its N-terminal glycine loop domain. J Invest Dermatol 2004; 122:747.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/60\" class=\"nounderline abstract_t\">Simon M, Jonca N, Guerrin M, et al. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 2001; 276:20292.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/61\" class=\"nounderline abstract_t\">Samuelov L, Sprecher E. Peeling off the genetics of atopic dermatitis-like congenital disorders. J Allergy Clin Immunol 2014; 134:808.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/62\" class=\"nounderline abstract_t\">Dicken CH. Peeling skin syndrome. J Am Acad Dermatol 1985; 13:158.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/63\" class=\"nounderline abstract_t\">Srinivasaraghavan R, Krishnamurthy S, Chandar R, et al. Immunoglobulin A nephropathy in association with generalized inflammatory peeling skin syndrome. Pediatr Dermatol 2015; 32:244.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/64\" class=\"nounderline abstract_t\">Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am 2015; 35:161.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/65\" class=\"nounderline abstract_t\">Igawa S, Kishibe M, Honma M, et al. Aberrant distribution patterns of corneodesmosomal components of tape-stripped corneocytes in atopic dermatitis and related skin conditions (ichthyosis vulgaris, Netherton syndrome and peeling skin syndrome type B). J Dermatol Sci 2013; 72:54.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/66\" class=\"nounderline abstract_t\">Samuelov L, Sprecher E. Inherited desmosomal disorders. Cell Tissue Res 2015; 360:457.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/67\" class=\"nounderline abstract_t\">Bitoun E, Micheloni A, Lamant L, et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet 2003; 12:2417.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/68\" class=\"nounderline abstract_t\">Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25:141.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/69\" class=\"nounderline abstract_t\">M&auml;gert HJ, St&auml;ndker L, Kreutzmann P, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999; 274:21499.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/70\" class=\"nounderline abstract_t\">Mizuno Y, Suga Y, Muramatsu S, et al. A Japanese infant with localized ichthyosis linearis circumflexa on the palms and soles harbouring a compound heterozygous mutation in the SPINK5 gene. Br J Dermatol 2005; 153:661.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/71\" class=\"nounderline abstract_t\">Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr Dermatol 1996; 13:183.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/72\" class=\"nounderline abstract_t\">Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res 2013; 351:289.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/73\" class=\"nounderline abstract_t\">Mizuno Y, Suga Y, Haruna K, et al. A case of a Japanese neonate with congenital ichthyosiform erythroderma diagnosed as Netherton syndrome. Clin Exp Dermatol 2006; 31:677.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/74\" class=\"nounderline abstract_t\">El Shabrawi-Caelen L, Smolle J, Metze D, et al. Generalized exfoliative erythroderma since birth. Netherton syndrome. Arch Dermatol 2004; 140:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/75\" class=\"nounderline abstract_t\">Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int J Dermatol 2006; 45:693.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/76\" class=\"nounderline abstract_t\">Haliasos EC, Kerner M, Jaimes-Lopez N, et al. Dermoscopy for the pediatric dermatologist part I: dermoscopy of pediatric infectious and inflammatory skin lesions and hair disorders. Pediatr Dermatol 2013; 30:163.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/77\" class=\"nounderline abstract_t\">Burk C, Hu S, Lee C, Connelly EA. Netherton syndrome and trichorrhexis invaginata--a novel diagnostic approach. Pediatr Dermatol 2008; 25:287.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/78\" class=\"nounderline abstract_t\">Rakowska A, Kowalska-Oledzka E, Slowinska M, et al. Hair shaft videodermoscopy in netherton syndrome. Pediatr Dermatol 2009; 26:320.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/79\" class=\"nounderline abstract_t\">Macknet CA, Morkos A, Job L, et al. An infant with Netherton syndrome and persistent pulmonary hypertension requiring extracorporeal membrane oxygenation. Pediatr Dermatol 2008; 25:368.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/80\" class=\"nounderline abstract_t\">Pohl M, Zimmerhackl LB, Hausser I, et al. Acute bilateral renal vein thrombosis complicating Netherton syndrome. Eur J Pediatr 1998; 157:157.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/81\" class=\"nounderline abstract_t\">Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013; 45:1244.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/82\" class=\"nounderline abstract_t\">Schlipf NA, Vahlquist A, Teigen N, et al. Whole-exome sequencing identifies novel autosomal recessive DSG1 mutations associated with mild SAM syndrome. Br J Dermatol 2016; 174:444.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/83\" class=\"nounderline abstract_t\">Cheng R, Yan M, Ni C, et al. Report of Chinese family with severe dermatitis, multiple allergies and metabolic wasting syndrome caused by novel homozygous desmoglein-1 gene mutation. J Dermatol 2016; 43:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/84\" class=\"nounderline abstract_t\">D&#259;nescu S, Leppert J, Cosgarea R, et al. Compound heterozygosity for dominant and recessive DSG1 mutations in a patient with atypical SAM syndrome (severe dermatitis, multiple allergies, metabolic wasting). J Eur Acad Dermatol Venereol 2017; 31:e144.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/85\" class=\"nounderline abstract_t\">McAleer MA, Pohler E, Smith FJ, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol 2015; 136:1268.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/86\" class=\"nounderline abstract_t\">Has C, Jakob T, He Y, et al. Loss of desmoglein 1 associated with palmoplantar keratoderma, dermatitis and multiple allergies. Br J Dermatol 2015; 172:257.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/87\" class=\"nounderline abstract_t\">Ishida-Yamamoto A, Igawa S. Genetic skin diseases related to desmosomes and corneodesmosomes. J Dermatol Sci 2014; 74:99.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/88\" class=\"nounderline abstract_t\">Mogensen TH. STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT 2013; 2:e23435.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/89\" class=\"nounderline abstract_t\">Gschwandtner M, Mildner M, Mlitz V, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013; 68:37.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/90\" class=\"nounderline abstract_t\">Komatsu N, Suga Y, Saijoh K, et al. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J Invest Dermatol 2006; 126:2338.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/91\" class=\"nounderline abstract_t\">Tan X, Bertonati C, Qin L, et al. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins. Eur J Med Chem 2013; 70:661.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/92\" class=\"nounderline abstract_t\">Tan X, Furio L, Reboud-Ravaux M, et al. 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett 2013; 23:4547.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/93\" class=\"nounderline abstract_t\">Fischer J, Wu Z, Kantyka T, et al. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury. J Invest Dermatol 2014; 134:1305.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/94\" class=\"nounderline abstract_t\">Teixeira TS, Freitas RF, Abrah&atilde;o O Jr, et al. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. Bioorg Med Chem Lett 2011; 21:6112.</a></li><li><a href=\"https://www.uptodate.com/contents/peeling-skin-syndrome/abstract/95\" class=\"nounderline abstract_t\">Vasileiou Z, Barlos KK, Gatos D, et al. Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation. Biopolymers 2010; 94:339.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15512 Version 6.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H316953238\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H109776710\" id=\"outline-link-H109776710\">INTRODUCTION</a></li><li><a href=\"#H109776716\" id=\"outline-link-H109776716\">ACRAL PEELING SKIN SYNDROME</a><ul><li><a href=\"#H316952002\" id=\"outline-link-H316952002\">Epidemiology</a></li><li><a href=\"#H109776724\" id=\"outline-link-H109776724\">Pathogenesis</a></li><li><a href=\"#H52453532\" id=\"outline-link-H52453532\">Pathology</a></li><li><a href=\"#H109776736\" id=\"outline-link-H109776736\">Clinical manifestations</a></li><li><a href=\"#H109776748\" id=\"outline-link-H109776748\">Diagnosis</a></li><li><a href=\"#H109776754\" id=\"outline-link-H109776754\">Differential diagnosis</a><ul><li><a href=\"#H316952205\" id=\"outline-link-H316952205\">- Localized epidermolysis bullosa simplex</a></li><li><a href=\"#H316952212\" id=\"outline-link-H316952212\">- Exfoliative ichthyosis</a></li><li><a href=\"#H316952219\" id=\"outline-link-H316952219\">- Erythrokeratolysis hiemalis (keratolytic winter erythema)</a></li><li><a href=\"#H109776770\" id=\"outline-link-H109776770\">- Keratolysis exfoliativa</a></li><li><a href=\"#H109776782\" id=\"outline-link-H109776782\">- Dyshidrotic eczema</a></li><li><a href=\"#H109776788\" id=\"outline-link-H109776788\">- Fungal infection and dermatophytid reaction</a></li><li><a href=\"#H109776800\" id=\"outline-link-H109776800\">- Allergic contact dermatitis</a></li><li><a href=\"#H109776806\" id=\"outline-link-H109776806\">- Autoimmune bullous disease</a></li></ul></li><li><a href=\"#H109776812\" id=\"outline-link-H109776812\">Management</a></li><li><a href=\"#H316952558\" id=\"outline-link-H316952558\">Genetic testing</a></li></ul></li><li><a href=\"#H109776818\" id=\"outline-link-H109776818\">GENERALIZED NONINFLAMMATORY PEELING SKIN SYNDROME</a><ul><li><a href=\"#H109776826\" id=\"outline-link-H109776826\">Pathogenesis</a></li><li><a href=\"#H316952681\" id=\"outline-link-H316952681\">Pathology</a></li><li><a href=\"#H109776832\" id=\"outline-link-H109776832\">Clinical manifestations</a></li><li><a href=\"#H109776844\" id=\"outline-link-H109776844\">Diagnosis</a></li><li><a href=\"#H109776850\" id=\"outline-link-H109776850\">Differential diagnosis</a><ul><li><a href=\"#H109776857\" id=\"outline-link-H109776857\">- Staphylococcal scalded skin syndrome</a></li><li><a href=\"#H109776863\" id=\"outline-link-H109776863\">- Epidermolysis bullosa simplex superficialis</a></li><li><a href=\"#H109776869\" id=\"outline-link-H109776869\">- Superficial epidermolytic ichthyosis</a></li></ul></li><li><a href=\"#H109776875\" id=\"outline-link-H109776875\">Management</a></li></ul></li><li><a href=\"#H109776881\" id=\"outline-link-H109776881\">GENERALIZED INFLAMMATORY PEELING SKIN SYNDROME</a><ul><li><a href=\"#H109776889\" id=\"outline-link-H109776889\">Pathogenesis</a></li><li><a href=\"#H316952963\" id=\"outline-link-H316952963\">Pathology</a></li><li><a href=\"#H109776895\" id=\"outline-link-H109776895\">Clinical manifestations</a></li><li><a href=\"#H109776907\" id=\"outline-link-H109776907\">Diagnosis</a></li><li><a href=\"#H109776913\" id=\"outline-link-H109776913\">Differential diagnosis</a><ul><li><a href=\"#H109776921\" id=\"outline-link-H109776921\">- Atopic dermatitis</a></li><li><a href=\"#H316953004\" id=\"outline-link-H316953004\">- Netherton syndrome</a></li><li><a href=\"#H316953017\" id=\"outline-link-H316953017\">- SAM syndrome</a></li><li><a href=\"#H316953034\" id=\"outline-link-H316953034\">- Hyper-IgE syndrome</a></li></ul></li><li><a href=\"#H109776934\" id=\"outline-link-H109776934\">Management</a></li></ul></li><li><a href=\"#H316953238\" id=\"outline-link-H316953238\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15512|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=DERM/100421\" class=\"graphic graphic_algorithm\">- Peeling skin syndrome</a></li></ul></li><li><div id=\"DERM/15512|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/86390\" class=\"graphic graphic_picture\">- EB simplex localized 1</a></li><li><a href=\"image.htm?imageKey=DERM/86391\" class=\"graphic graphic_picture\">- EB simplex localized 2</a></li><li><a href=\"image.htm?imageKey=PC/55722\" class=\"graphic graphic_picture\">- Dyshidrotic eczema hand</a></li><li><a href=\"image.htm?imageKey=PC/75738\" class=\"graphic graphic_picture\">- Dyshidrotic eczema foot</a></li><li><a href=\"image.htm?imageKey=DERM/82787\" class=\"graphic graphic_picture\">- Tinea pedis bullous</a></li><li><a href=\"image.htm?imageKey=DERM/52664\" class=\"graphic graphic_picture\">- Autoeczematization on hand</a></li><li><a href=\"image.htm?imageKey=DERM/50357\" class=\"graphic graphic_picture\">- Dyshidrosiform bullous pemphigoid</a></li><li><a href=\"image.htm?imageKey=DERM/100995\" class=\"graphic graphic_picture\">- Linear IgA dermatosis palmar</a></li><li><a href=\"image.htm?imageKey=DERM/72261\" class=\"graphic graphic_picture\">- Staphylococcal scalded skin syndrome - trunk</a></li><li><a href=\"image.htm?imageKey=DERM/87482\" class=\"graphic graphic_picture\">- Ichthyosis linearis circumflexa in Netherton syndrome</a></li><li><a href=\"image.htm?imageKey=DERM/87481\" class=\"graphic graphic_picture\">- Netherton syndrome</a></li><li><a href=\"image.htm?imageKey=ALLRG/61049\" class=\"graphic graphic_picture\">- Severe eczema hyper IgE</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-palmoplantar-eczema-dyshidrotic-eczema\" class=\"medical medical_review\">Acute palmoplantar eczema (dyshidrotic eczema)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atopic-dermatitis-eczema-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autosomal-dominant-hyperimmunoglobulin-e-syndrome\" class=\"medical medical_review\">Autosomal dominant hyperimmunoglobulin E syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-allergic-contact-dermatitis\" class=\"medical medical_review\">Clinical features and diagnosis of allergic contact dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=combined-immunodeficiencies\" class=\"medical medical_review\">Combined immunodeficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=common-allergens-in-allergic-contact-dermatitis\" class=\"medical medical_review\">Common allergens in allergic contact dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">Dermatophyte (tinea) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-epidermolysis-bullosa\" class=\"medical medical_review\">Diagnosis of epidermolysis bullosa</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-classification-and-clinical-features-of-epidermolysis-bullosa\" class=\"medical medical_review\">Epidemiology, pathogenesis, classification, and clinical features of epidermolysis bullosa</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-and-classification-of-the-inherited-ichthyoses\" class=\"medical medical_review\">Overview and classification of the inherited ichthyoses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-epidermolysis-bullosa\" class=\"medical medical_review\">Overview of the management of epidermolysis bullosa</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vesiculopustular-and-bullous-lesions-in-the-newborn-and-infant\" class=\"medical medical_review\">Vesiculopustular and bullous lesions in the newborn and infant</a></li></ul></div></div>","javascript":null}